Acta Scientific Pharmaceutical Sciences (ISSN: 2581-883X)

Case Report Volume 4 Issue 7

A Case Report on Colistin Induced Myasthenia Gravis

Pulimi Divya Priyanka1*, Vithya Alhas1, Farhan1 and Manoharan2

1Department of Pharmacy Practice, Al-Ameen College of Pharmacy, Bangalore, India
2Department of Nephrology, St. Philomena’s Hospital, Bangalore, India

*Corresponding Author: Pulimi Divya Priyanka, Department of Pharmacy Practice, Al-Ameen College of Pharmacy, Bangalore, India.

Received: March 20, 2020; Published: June 30, 2020



A 60-year-old Male admitted to Surgical ward of tertiary care hospital with the complaints of wound debarment on left leg and left thigh abscess since two months and foul smell from 15 days associated with complaints of pain in both lower limbs. He is a known case of Type II DM from 10 years, HTN since one year, CLD, CKD from one and half year and is on Haemodialysis and was on oral medication. After adequate preoperative work up, the patient was taken for surgery with high risk and underwent skin grafting and withstood the surgery. The patient culture reported growth of Pseudomonas aeruginosa and on first day IV Colistin 1 Million Units TID, IV Clindamycin 600 mg BD and IV Meropenem 1 gm TID were prescribed. The patient developed Myasthenia gravis and Neurologist confirmed it as Colistin induced and the same was stopped on 13th day. Neostigmine 2.5 mg BD was prescribed and extubated. He was treated with other antibiotics and supportive treatment. Patient improved symptomatically after the withdrawal of Colistin and discharged in a stable condition with multivitamins, Anti-Hypertensives and Anti-Diabetic medications.

Keywords: Colistin; Myasthenia Gravis; Neostigmine



  1. Falagas ME and Kasiakou SK. “Toxicity of polymyxins: a systematic review of the evidence from old and recent studies”. Critical Care (London, England) 1 (2006): R27.
  2. Kasper D and Harrison T. “Harrison's principles of internal medicine”. 19th New York: McGraw-Hill, Medical Publication. Division (2015).


Citation: Pulimi Divya Priyanka., et al “A Case Report on Colistin Induced Myasthenia Gravis".Acta Scientific Pharmaceutical Sciences 4.7 (2020): 16-18.


Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor1.197

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US